|
Gene: HECTD1 |
Gene summary for HECTD1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | HECTD1 | Gene ID | 25831 |
Gene name | HECT domain E3 ubiquitin protein ligase 1 | |
Gene Alias | EULIR | |
Cytomap | 14q12 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9ULT8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
25831 | HECTD1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.06e-19 | -5.59e-01 | 0.0155 |
25831 | HECTD1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.18e-05 | 4.85e-01 | -0.1954 |
25831 | HECTD1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.17e-09 | -5.29e-01 | -0.1207 |
25831 | HECTD1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 6.67e-03 | -5.25e-01 | -0.2061 |
25831 | HECTD1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.99e-06 | -4.19e-01 | 0.3859 |
25831 | HECTD1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.98e-03 | -5.06e-01 | 0.2585 |
25831 | HECTD1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.90e-08 | -4.61e-01 | 0.3005 |
25831 | HECTD1 | F007 | Human | Colorectum | FAP | 3.76e-04 | -3.83e-01 | 0.1176 |
25831 | HECTD1 | A001-C-207 | Human | Colorectum | FAP | 1.15e-03 | -1.84e-01 | 0.1278 |
25831 | HECTD1 | A015-C-203 | Human | Colorectum | FAP | 3.58e-31 | -3.49e-01 | -0.1294 |
25831 | HECTD1 | A015-C-204 | Human | Colorectum | FAP | 9.65e-05 | -2.46e-01 | -0.0228 |
25831 | HECTD1 | A014-C-040 | Human | Colorectum | FAP | 6.94e-05 | -3.05e-01 | -0.1184 |
25831 | HECTD1 | A002-C-201 | Human | Colorectum | FAP | 1.46e-15 | -3.66e-01 | 0.0324 |
25831 | HECTD1 | A002-C-203 | Human | Colorectum | FAP | 1.05e-06 | -1.69e-01 | 0.2786 |
25831 | HECTD1 | A001-C-119 | Human | Colorectum | FAP | 2.16e-05 | -1.45e-01 | -0.1557 |
25831 | HECTD1 | A001-C-108 | Human | Colorectum | FAP | 1.47e-19 | -1.75e-01 | -0.0272 |
25831 | HECTD1 | A002-C-205 | Human | Colorectum | FAP | 6.00e-25 | -1.93e-01 | -0.1236 |
25831 | HECTD1 | A001-C-104 | Human | Colorectum | FAP | 1.80e-02 | -7.51e-02 | 0.0184 |
25831 | HECTD1 | A015-C-005 | Human | Colorectum | FAP | 1.02e-09 | -4.07e-01 | -0.0336 |
25831 | HECTD1 | A015-C-006 | Human | Colorectum | FAP | 3.28e-16 | -4.08e-01 | -0.0994 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0042176 | Colorectum | AD | regulation of protein catabolic process | 160/3918 | 391/18723 | 1.06e-19 | 7.34e-17 | 160 |
GO:0072659 | Colorectum | AD | protein localization to plasma membrane | 122/3918 | 284/18723 | 2.86e-17 | 1.49e-14 | 122 |
GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
GO:1903362 | Colorectum | AD | regulation of cellular protein catabolic process | 109/3918 | 255/18723 | 2.14e-15 | 6.08e-13 | 109 |
GO:0010498 | Colorectum | AD | proteasomal protein catabolic process | 174/3918 | 490/18723 | 3.18e-14 | 7.66e-12 | 174 |
GO:0031331 | Colorectum | AD | positive regulation of cellular catabolic process | 156/3918 | 427/18723 | 4.68e-14 | 1.05e-11 | 156 |
GO:1990778 | Colorectum | AD | protein localization to cell periphery | 129/3918 | 333/18723 | 5.51e-14 | 1.15e-11 | 129 |
GO:1903050 | Colorectum | AD | regulation of proteolysis involved in cellular protein catabolic process | 92/3918 | 221/18723 | 2.04e-12 | 3.19e-10 | 92 |
GO:0045732 | Colorectum | AD | positive regulation of protein catabolic process | 92/3918 | 231/18723 | 3.85e-11 | 4.47e-09 | 92 |
GO:0043161 | Colorectum | AD | proteasome-mediated ubiquitin-dependent protein catabolic process | 141/3918 | 412/18723 | 1.77e-10 | 1.68e-08 | 141 |
GO:1905475 | Colorectum | AD | regulation of protein localization to membrane | 73/3918 | 175/18723 | 3.37e-10 | 2.93e-08 | 73 |
GO:0045862 | Colorectum | AD | positive regulation of proteolysis | 129/3918 | 372/18723 | 4.04e-10 | 3.46e-08 | 129 |
GO:0061136 | Colorectum | AD | regulation of proteasomal protein catabolic process | 75/3918 | 187/18723 | 1.65e-09 | 1.20e-07 | 75 |
GO:2000058 | Colorectum | AD | regulation of ubiquitin-dependent protein catabolic process | 68/3918 | 164/18723 | 1.82e-09 | 1.31e-07 | 68 |
GO:1903076 | Colorectum | AD | regulation of protein localization to plasma membrane | 48/3918 | 104/18723 | 7.17e-09 | 4.36e-07 | 48 |
GO:1904375 | Colorectum | AD | regulation of protein localization to cell periphery | 54/3918 | 125/18723 | 1.52e-08 | 9.00e-07 | 54 |
GO:1903364 | Colorectum | AD | positive regulation of cellular protein catabolic process | 62/3918 | 155/18723 | 4.66e-08 | 2.51e-06 | 62 |
GO:0032434 | Colorectum | AD | regulation of proteasomal ubiquitin-dependent protein catabolic process | 54/3918 | 134/18723 | 2.51e-07 | 1.02e-05 | 54 |
GO:1903052 | Colorectum | AD | positive regulation of proteolysis involved in cellular protein catabolic process | 53/3918 | 133/18723 | 4.93e-07 | 1.85e-05 | 53 |
GO:2000060 | Colorectum | AD | positive regulation of ubiquitin-dependent protein catabolic process | 44/3918 | 107/18723 | 1.65e-06 | 5.03e-05 | 44 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HECTD1 | SNV | Missense_Mutation | novel | c.1907N>C | p.Asn636Thr | p.N636T | Q9ULT8 | protein_coding | tolerated(0.25) | benign(0.013) | TCGA-CV-7418-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
HECTD1 | SNV | Missense_Mutation | novel | c.5742N>G | p.Ile1914Met | p.I1914M | Q9ULT8 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.924) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HECTD1 | SNV | Missense_Mutation | novel | c.541N>A | p.Asp181Asn | p.D181N | Q9ULT8 | protein_coding | deleterious(0.02) | possibly_damaging(0.629) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HECTD1 | SNV | Missense_Mutation | novel | c.6611C>G | p.Ser2204Cys | p.S2204C | Q9ULT8 | protein_coding | deleterious(0.02) | possibly_damaging(0.82) | TCGA-P3-A6T7-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
HECTD1 | SNV | Missense_Mutation | novel | c.6207N>A | p.Ser2069Arg | p.S2069R | Q9ULT8 | protein_coding | tolerated(0.68) | benign(0.282) | TCGA-QK-A6II-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
HECTD1 | SNV | Missense_Mutation | c.494C>T | p.Ser165Phe | p.S165F | Q9ULT8 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-RS-A6TP-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
HECTD1 | SNV | Missense_Mutation | novel | c.6794C>G | p.Pro2265Arg | p.P2265R | Q9ULT8 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-HC-A9TH-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Hormone Therapy | firmagon | SD |
HECTD1 | SNV | Missense_Mutation | novel | c.6285N>G | p.Ile2095Met | p.I2095M | Q9ULT8 | protein_coding | deleterious(0) | benign(0.367) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
HECTD1 | SNV | Missense_Mutation | novel | c.2729N>G | p.Glu910Gly | p.E910G | Q9ULT8 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
HECTD1 | SNV | Missense_Mutation | novel | c.2558N>A | p.Arg853His | p.R853H | Q9ULT8 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |